Journal: Poultry Science

Article Title: Overexpression of irisin reduces embryonic and diet-induced hepatic lipid accumulation in chickens

doi: 10.1016/j.psj.2026.106831

Figure Lengend Snippet: Lipid accumulation in the liver of 19-day chicken embryos was reduced by lentivirus-mediated overexpression of irisin. A Schematic diagram of the lentiviral vector structure. B Effects of lentivirus -mediated overexpression of irisin on chicken hatchability. Data analysis was performed using the chi-square test. C The levels of exogenous irisin in plasma were measured in 19-day-old chicken embryos. D Triglyceride (TG) and total cholesterol (TC) content in chicken embryonic liver. E H&E and Oil Red O staining of chicken embryonic liver. In the Control group, numerous lipid droplets were observed within hepatocytes, accompanied by extensive cytoplasmic vacuolization and indistinct hepatic cord architecture. Compared to the Control group, the Irisin group exhibited a significant reduction in lipid droplets, marked improvement in cytoplasmic vacuolization, and clear, intact hepatic cord structure. F Effects of irisin on the expression levels of lipid-related genes in chicken embryonic liver.

Article Snippet: Hepatic and plasma triglycerides (TG) and total cholesterol (TC) levels were measured using commercial kits (Nanjing Jiancheng Bioengineering Institute, China) according to the manufacturer's protocols.

Techniques: Over Expression, Plasmid Preparation, Clinical Proteomics, Staining, Control, Expressing

Journal: International Journal of Cardiology. Cardiovascular Risk and Prevention

Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis

doi: 10.1016/j.ijcrp.2026.200590

Figure Lengend Snippet: Summary of included studies.

Article Snippet: Clavijoa, 2023 , RCT, Double-blind , USA , 6 months , Evolocumab 420 mg SC q4w , placebo , 35 , 35 , 70 , Patients aged 40–85 years with a diagnosis of atherosclerotic cardiovascular disease and PAD (Rutherford class I-VI), confirmed by an ankle-brachial index (ABI) ≤0.9 at rest or ≤0.8 after exercise, angiography, duplex ultrasound, or a history of lower extremity surgical or endovascular revascularization. Patients had to be at least one month from their most recent intervention, stable on maximal tolerated lipid-lowering therapy for at least four weeks, and have a fasting LDL cholesterol ≥55 mg/dL or non-HDL cholesterol ≥80 mg/dL. , MWT at 6 months , After six months, Evolocumab significantly improved MWT, FMD, Carotid IMT, and plasma MRP-14 levels. In contrast, changes in pain-free walking time, ABI, TBI, transcutaneous oxygen pressure, oxLDL, and sCD36 were not statistically significant..

Techniques: Control, Biomarker Discovery, Clinical Proteomics, Activation Assay

Journal: International Journal of Cardiology. Cardiovascular Risk and Prevention

Article Title: Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis

doi: 10.1016/j.ijcrp.2026.200590

Figure Lengend Snippet: Summary of included studies.

Article Snippet: Clavijoa, 2023 , RCT, Double-blind , USA , 6 months , Evolocumab 420 mg SC q4w , placebo , 35 , 35 , 70 , Patients aged 40–85 years with a diagnosis of atherosclerotic cardiovascular disease and PAD (Rutherford class I-VI), confirmed by an ankle-brachial index (ABI) ≤0.9 at rest or ≤0.8 after exercise, angiography, duplex ultrasound, or a history of lower extremity surgical or endovascular revascularization. Patients had to be at least one month from their most recent intervention, stable on maximal tolerated lipid-lowering therapy for at least four weeks, and have a fasting LDL cholesterol ≥55 mg/dL or non-HDL cholesterol ≥80 mg/dL. , MWT at 6 months , After six months, Evolocumab significantly improved MWT, FMD, Carotid IMT, and plasma MRP-14 levels. In contrast, changes in pain-free walking time, ABI, TBI, transcutaneous oxygen pressure, oxLDL, and sCD36 were not statistically significant..

Techniques: Control, Biomarker Discovery, Clinical Proteomics, Activation Assay